Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
RESEARCH TOOLSreports
OTLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $12.85
Previous CloseN/A
Volume358.39K
Average Volume (3M)802.28K
Market Cap
$54.75M
Enterprise Value$142.47M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.68
Next Earnings
May 14, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.94
Shares Outstanding32,017,178
10 Day Avg. Volume580,322
30 Day Avg. Volume802,280
Standard Deviation0.37
R-Squared0.00704
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside204.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Strategic CollaborationOutlook has entered into a strategic collaboration with Cencora to support the global commercial launch of Lytenava.
Bears Say
FDA Regulatory UncertaintyIt remains unclear how much weight the FDA will place on the finding of non-inferiority margin at week 12, as the 8-week readout was the only preset endpoint of the NORSE 8 study.
Trial Endpoint FailureONS-5010 missed the primary endpoint of non-inferiority at week 8 set forth in the special protocol assessment with the FDA.
---
Ownership Overview
27.93% Insiders
4.07% Mutual Funds
1.35% Other Institutional Investors
62.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.87 and its highest was $12.85 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $54.75M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 82 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Feb 14, 2025. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.76 by -$0.13.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.61.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 32,017,178 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.76. Following the earnings report the stock price went up 1.63%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
---
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (204.88% Upside)
$5.00 (204.88% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.23%
12-Months-Change
Fundamentals
Return on Equity
<0.01%
Trailing 12-Months
Asset Growth
-21.58%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Cranbury, NJ.
---
OTLK Stock 12 Month Forecast
Average Price Target
$5.00
▲(204.88% Upside)
Technical Analysis
Best Analysts Covering OTLK
1 Year
1 Year Success Rate
2/19 ratings generated profit
1 Year Average Return
-50.48%
reiterated a buy rating 4 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 10.53% of your transactions generating a profit, with an average return of -50.48% per trade.
---